Quidel

The firm saw a 36 percent increase in influenza product sales compared to the third quarter last year.

The FDA-cleared panel includes tests for salmonella, Shiga toxin-producing Escherichia coli, Shigella, Campylobacter, and Cryptosporidium.

The index, which slightly underperformed the Dow Jones, had a smaller loss in August than in the previous month.

The firm experienced a 30 percent jump in sales of immunoassays, attributed in part to a $6.2 million increase in influenza revenues year-over-year.

Flu test sales were the second-highest for a quarter in the firm's history but were still $17.4 million lower than the year-ago quarter due to a much less intense flu season.

The firm expects Q4 revenues to be in the $132 million to $133 million range, up 15 to 16 percent from a year ago and consistent with the consensus Wall Street estimate.

The firm saw 60 percent revenue growth in molecular diagnostics, including 88 percent growth in its Solana system.